

PubMed

**Format:** Abstract**Full text links**

Clin Pharmacol Ther. 2009 Mar;85(3):273-6. doi: 10.1038/clpt.2008.213. Epub 2008 Nov 12.



## Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.

Sachse-Seeboth C<sup>1</sup>, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde SV, Brockmüller J.

### Author information

### Abstract

The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered 9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9\*2 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9\*3/\*3 homozygotes than in CYP2C9\*1/\*1 homozygotes. CYP2C9\*3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9\*3 variant may influence both the therapeutic and adverse effects of THC.

PMID: 19005461 DOI: [10.1038/clpt.2008.213](https://doi.org/10.1038/clpt.2008.213)

[Indexed for MEDLINE]

**Publication type, MeSH terms, Substances** **LinkOut - more resources**